Screening EGFR Mutations in NSCLC by Immunohistochemistry

被引：0
|
作者：
Gaber, Rania [1 ]
Watermann, Iris [2 ]
Vollmer, Ekkehard [2 ]
Goldmann, Torsten [2 ]
机构：
[1] Univ Alexandria, Fac Med, Pathol, Alexandria, Egypt
[2] Res Ctr Borstel, Clin & Expt Pathol, Borstel, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
EGFR mutations; DNA sequencing; NSCLC; Immunohistochemistry;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-015
引用
收藏
页码：S582 / S583
页数：2
相关论文
共 50 条
  • [11] EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients
    Wang, Zhen
    Wu, Yi Long
    Zhang, Guo Chun
    Zhou, Qing
    Xu, Chong Rui
    Guo, Ai Lin
    ONKOLOGIE, 2008, 31 (04): : 174 - 178
  • [12] Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics
    Wei Feng
    Xi Chen
    Shao-xing Guan
    Hong-lian Ruan
    Yan Huang
    Hui-zhen Zhang
    Yun-peng Yang
    Wen-feng Fang
    Hong-yun Zhao
    Wei Zhuang
    Shuang Xin
    You-hao Chen
    Fei Wang
    Yue Gao
    Min Huang
    Xue-ding Wang
    Li Zhang
    Acta Pharmacologica Sinica, 2022, 43 : 1857 - 1864
  • [13] IMMUNOHISTOCHEMISTRY AS A PREDICTOR OF EGFR MUTATIONS: A RETROSPECTIVE CASE-CONTROL STUDY
    Corrales-Rodriguez, Luis
    Abbas, Jad
    Ramos-Esquivel, Allan
    Araya, Monica
    Maria Casco, Ana
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S176 - S177
  • [14] Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma
    Hofman, P.
    Ilie, M.
    Hofman, V.
    Roux, S.
    Valent, A.
    Bernheim, A.
    Alifano, M.
    Leroy-Ladurie, F.
    Vaylet, F.
    Rouquette, I.
    Validire, P.
    Beau-Faller, M.
    Lacroix, L.
    Soria, J. C.
    Fouret, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1738 - 1743
  • [15] Coexistence of three EGFR mutations in an NSCLC patient: A brief report
    Belardinilli, Francesca
    Gradilone, Angela
    Gelibter, Alain
    Zani, Massimo
    Occhipinti, Mario
    Ferraro, Sergio
    Nicolazzo, Chiara
    Coppa, Anna
    Giannini, Giuseppe
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04) : 545 - 548
  • [16] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
    Bazhenova, Lyudmila
    Minchom, Anna
    Viteri, Santiago
    Bauml, Joshua M.
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Manuel Trigo, Jose
    Backenroth, Daniel
    Li, Tracy
    Londhe, Anil
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2021, 162 : 154 - 161
  • [17] Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients
    Mohorcic, Katja
    Kern, Izidor
    Janzic, Urska
    Hitij, Nina Turnsek
    Rot, Mitja
    Cufer, Tanja
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S388 - S389
  • [18] Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
    Marchetti, Antonio
    Palma, John F.
    Felicioni, Lara
    De Pas, Tommaso M.
    Chiari, Rita
    Del Grammastro, Maela
    Filice, Giampaolo
    Ludovini, Vienna
    Brandes, Alba A.
    Chella, Antonio
    Malorgio, Francesco
    Guglielmi, Flavio
    De Tursi, Michele
    Santoro, Armando
    Crino, Lucio
    Buttitta, Fiamma
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) : 1437 - 1443
  • [19] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
    Mohorcic, K.
    Janzic, A.
    Janzic, U.
    Rot, M.
    Kern, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
  • [20] Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Keam, Bhumsuk
    Ku, Ja-Lok
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1556 - 1566
12345